Skip navigation

Scott Minick

Board Member

Mr. Minick is a veteran biopharma executive and venture capital investor, with a strong track record growing small and mid-sized companies through acquisitions and IPOs. Mr. Minick served on the boards of numerous public and private biotechnology companies. During his tenure as CEO of BIND Therapeutics, he built a broad cancer clinical pipeline based on innovative nanotechnology from MIT and Harvard, and completed a groundbreaking IPO in 2013.

Before joining BIND, Mr. Minick was a Managing Director of ARCH Venture Partners, a top tier biotechnology venture fund, where he also served as Executive Chairman of several ARCH portfolio companies. Previously, he was President and Chief Operating Officer of SEQUUS Pharmaceuticals, Inc., where he played a pivotal role in the development, regulatory approval, and commercial launch of cancer therapeutic, Doxil®. Mr. Minick also served as Chairman of California Pacific Medical Center and a Director of Beth Israel Deaconess Medical Center, two leading healthcare systems.